Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J1FB
|
|||
| Former ID |
DCL000382
|
|||
| Drug Name |
GSK586529
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z] | Phase 1 | [1] | |
| Depression [ICD-11: 6A70-6A7Z] | Phase 1 | [1] | ||
| Company |
GSK
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Corticotropin-releasing factor receptor 1 (CRHR1) | Target Info | Antagonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Long-term depression | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Panther Pathway | Cortocotropin releasing factor receptor signaling pathway | |||
| Reactome | Class B/2 (Secretin family receptors) | |||
| G alpha (s) signalling events | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Myometrial Relaxation and Contraction Pathways | ||||
| Corticotropin-releasing hormone | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00703547) A First Time in Human Study of GSK586529 in Healthy Volunteers. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.